The Comprehensive Retatrutide FAQ

Retatrutide is an investigational peptide drug designed to activate three hormone receptors: GLP-1R, GIP-R, and glucagon receptor. It is being developed for the treatment of obesity and type 2 diabetes. As of 2026, retatrutide is in Phase 3 clinical trials and has not yet been approved by the FDA, TGA, or other regulatory authorities. The drug is administered as a weekly subcutaneous injection.

Retatrutide works through three simultaneous mechanisms: GLP-1 activation suppresses appetite and enhances glucose-dependent insulin secretion; GIP activation enhances the incretin effect and may affect metabolic rate; glucagon activation increases metabolic rate and promotes fat breakdown. Together, these three pathways produce weight loss through reduced food intake and increased energy expenditure, along with improvements in glucose control and metabolic health.

Based on Phase 2 data, retatrutide appears to have an acceptable safety profile. The most common side effects are gastrointestinal (nausea, diarrhea, constipation), which are typically mild to moderate and self-limiting. Serious adverse events have been rare in Phase 2 trials. However, Phase 3 trials with larger populations and longer durations are necessary to fully characterize long-term safety. Like all new drugs, retatrutide's complete safety profile will only be fully understood once it has been used in millions of patients over many years.

Regulatory approval timelines are uncertain but based on Phase 3 trial progress, FDA approval could potentially occur in late 2027 or early 2028. This is speculative; actual timelines depend on trial completion, data analysis, regulatory review, and any additional information requests. TGA approval in Australia might follow 6-12 months after FDA approval. Monitoring ClinicalTrials.gov and regulatory agency communications will provide the most current timeline information.